Tag: rucaparib

Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting

by Selina McKee | Jul 9, 2018 | News | 0

European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.

EU filing for Clovis’ Rubraca in ovarian cancer maintenance setting

by Selina McKee | Jun 5, 2018 | News | 0

Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

New US approval for Clovis’ Rubraca

by Selina McKee | Apr 9, 2018 | News | 0

Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.

Six new therapies backed for EU approval

by Selina McKee | Mar 28, 2018 | News | 0

Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Clovis’ ovarian cancer drug gets US priority review

by Selina McKee | Aug 24, 2016 | News | 0

Clovis’ PARP inhibitor rucaparib will get a speedy review from US regulators as a treatment for patients with certain forms of advanced ovarian cancer.